Grace Therapeutics (GRCE) Financials

Grace Therapeutics logo
$1.70 -0.03 (-1.45%)
Closing price 03:58 PM Eastern
Extended Trading
$1.70 -0.01 (-0.29%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Grace Therapeutics

Annual Income Statements for Grace Therapeutics

This table shows Grace Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 2/29/2016 2/28/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
-4.71 -8.05 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Consolidated Net Income / (Loss)
-4.71 -7.86 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Net Income / (Loss) Continuing Operations
-4.71 -8.05 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Total Pre-Tax Income
-4.71 -7.96 -17 -39 -26 -20 -10 -52 -15 -13 -9.49
Total Operating Income
-7.17 -7.87 -15 -34 -24 -16 -16 -52 -13 -17 -11
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.20 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.08 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
7.17 7.87 15 34 24 17 16 52 13 17 11
Selling, General & Admin Expense
1.53 2.45 3.12 4.54 5.80 5.52 9.26 7.61 6.68 7.17 8.67
Research & Development Expense
5.64 5.42 12 29 16 4.17 5.56 9.97 4.68 9.51 2.41
Total Other Income / (Expense), net
2.46 -0.09 -1.40 -4.96 -1.08 -3.26 5.12 0.18 -1.83 3.91 1.58
Interest & Investment Income
- - - - - - - 0.25 0.91 0.71 0.69
Other Income / (Expense), net
2.46 -0.09 -1.40 -4.96 -1.08 -3.26 5.12 -0.06 -2.74 3.20 0.90
Income Tax Expense
0.00 0.10 0.00 - - 0.00 -0.65 -9.54 -1.83 -3.20 -1.70
Basic Earnings per Share
($0.59) ($0.97) ($1.23) ($0.73) ($0.30) ($1.33) ($0.27) ($5.71) ($1.35) ($0.79) ($0.47)
Weighted Average Basic Shares Outstanding
10.66M 10.79M 17.49M 54.29M 84.58M 14.83M 36.84M 7.44M 9.53M 12.09M 16.51M
Diluted Earnings per Share
($0.59) ($0.97) ($1.23) ($0.73) ($0.30) ($1.33) ($0.27) ($5.71) ($1.35) ($0.79) ($0.47)
Weighted Average Diluted Shares Outstanding
10.66M 10.79M 17.49M 54.29M 84.58M 14.83M 36.84M 7.44M 9.53M 12.09M 16.51M
Weighted Average Basic & Diluted Shares Outstanding
10.66M 10.79M 17.49M 54.29M 84.58M 14.83M 36.84M 44.61M 9.40M - 16.27M

Quarterly Income Statements for Grace Therapeutics

This table shows Grace Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027 Q2 2027
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.27 -2.39 -4.57 -3.43 -4.16 -3.36 -0.94 -2.32 -1.18 -16 -2.13
Consolidated Net Income / (Loss)
-3.27 -2.39 -4.57 -3.43 -4.16 -3.36 -0.94 -2.32 -1.18 -16 -2.13
Net Income / (Loss) Continuing Operations
-3.27 -2.39 -4.57 -3.43 -4.16 -3.36 -0.94 -2.32 -1.18 -16 -2.13
Total Pre-Tax Income
-3.72 -2.60 -5.03 -4.28 -4.76 -3.36 -0.94 -2.32 -2.88 -16 -2.14
Total Operating Income
-2.09 -3.04 -2.75 -4.83 -3.70 -3.09 -2.53 -2.45 -3.01 -16 -2.29
Total Gross Profit
0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Total Revenue
0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue
0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses
2.09 3.04 2.75 4.83 3.70 3.09 2.53 2.45 3.01 16 2.29
Selling, General & Admin Expense
1.63 1.60 1.20 1.86 1.51 2.14 1.96 1.99 2.59 1.69 1.41
Research & Development Expense
0.46 1.44 0.07 2.98 2.19 0.96 0.57 0.46 0.42 0.70 0.89
Impairment Charge
- - - - - 0.00 0.00 - - 14 0.00
Total Other Income / (Expense), net
-1.63 0.44 -2.27 0.55 -1.06 -0.27 1.59 0.13 0.13 0.25 0.15
Interest & Investment Income
0.21 0.32 0.15 0.17 0.14 0.21 0.17 0.17 0.14 0.14 0.15
Other Income / (Expense), net
-1.84 0.13 -2.42 0.38 -1.19 -0.48 1.42 -0.04 -0.01 0.11 -0.00
Income Tax Expense
-0.45 -0.21 -0.45 -0.85 -0.61 0.00 0.00 0.00 -1.70 0.00 -0.01
Basic Earnings per Share
($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06) ($0.91) ($0.11)
Weighted Average Basic Shares Outstanding
7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M 17.27M 20.12M
Diluted Earnings per Share
($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06) ($0.91) ($0.11)
Weighted Average Diluted Shares Outstanding
7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M 17.27M 20.12M
Weighted Average Basic & Diluted Shares Outstanding
9.40M 9.40M 9.40M 10.14M 10.14M 13.83M 14.13M 15.47M 16.27M 21.04M 21.04M

Annual Cash Flow Statements for Grace Therapeutics

This table details how cash moves in and out of Grace Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 2/29/2016 2/28/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Net Change in Cash & Equivalents
1.28 5.66 -1.20 11 -2.63 37 -21 -2.46 -4.87 -0.87 -5.16
Net Cash From Operating Activities
-4.90 -4.66 -9.71 -24 23 -14 -17 -16 -12 -15 -8.87
Net Cash From Continuing Operating Activities
-4.90 -4.66 -9.71 -24 -23 -14 -17 -16 -12 -15 -8.87
Net Income / (Loss) Continuing Operations
-4.71 -7.86 -17 -39 -26 -20 -9.82 -42 -13 -9.57 -7.79
Consolidated Net Income / (Loss)
-4.71 -7.86 -17 -39 26 -20 -9.82 -42 -13 -9.57 -7.79
Depreciation Expense
0.04 0.14 0.27 0.38 -0.41 0.14 0.00 0.12 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income
-1.95 0.57 2.12 6.14 -0.47 4.44 -4.63 26 1.77 -5.69 -1.80
Changes in Operating Assets and Liabilities, net
-0.03 0.74 2.78 6.08 0.23 - -2.79 0.18 -1.26 0.34 0.72
Net Cash From Investing Activities
6.14 5.18 -0.32 -9.12 8.14 -9.86 -3.52 13 0.10 0.00 0.00
Net Cash From Continuing Investing Activities
6.14 5.18 -0.32 -9.12 8.14 -9.86 -3.52 13 0.10 0.00 0.00
Purchase of Investments
-8.98 -9.58 -0.02 -8.88 -1.92 -9.81 -35 -5.02 -6.55 -0.02 0.00
Sale and/or Maturity of Investments
15 17 0.00 0.00 10 0.02 31 18 6.57 0.02 0.00
Net Cash From Financing Activities
-0.00 5.18 8.84 44 13 59 0.00 0.30 7.36 14 3.71
Net Cash From Continuing Financing Activities
-0.00 5.18 8.84 44 13 59 0.00 0.30 7.36 14 3.71
Repurchase of Common Equity
-0.00 0.00 0.00 0.00 - - - - -0.16 -0.97 -0.33
Issuance of Common Equity
- - - - 6.98 59 0.00 0.30 7.50 15 0.00
Other Financing Activities, net
-0.00 -0.01 -0.00 -0.03 7.75 0.16 - - 0.02 0.00 4.04

Quarterly Cash Flow Statements for Grace Therapeutics

This table details how cash moves in and out of Grace Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027 Q2 2027
Period end date 9/30/2023 12/31/2023 3/31/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
2.73 -8.45 4.46 -4.10 11 -2.13 -3.14 1.81 -1.70 -3.22 7.56
Net Cash From Operating Activities
-4.76 -1.89 -2.09 -4.12 -2.95 -1.80 -3.14 -2.23 -1.70 -3.22 -1.78
Net Cash From Continuing Operating Activities
-4.76 -1.87 -2.09 -4.12 -2.95 -1.80 -3.14 -2.23 -1.70 -3.22 -1.78
Net Income / (Loss) Continuing Operations
-4.68 -2.39 -3.17 -4.16 0.64 -3.36 -0.94 -2.31 -1.18 -16 -2.13
Consolidated Net Income / (Loss)
-4.68 -2.39 -3.17 -4.16 0.64 -3.36 -0.94 -2.31 -1.18 -16 -2.13
Depreciation Expense
0.01 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
4.02 0.22 -0.57 1.34 -5.71 0.79 -1.22 0.15 -1.52 14 0.20
Changes in Operating Assets and Liabilities, net
-4.10 0.30 1.65 -1.30 2.12 0.77 -0.98 -0.07 1.00 -1.07 0.15
Net Cash From Financing Activities
7.36 - - - 14 -0.33 - 4.04 - 0.00 9.34
Net Cash From Continuing Financing Activities
7.36 - - - 14 -0.33 - 4.04 - 0.00 9.34
Repurchase of Common Equity
- - - - -0.97 -0.33 - - - 0.00 -0.66

Annual Balance Sheets for Grace Therapeutics

This table presents Grace Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
Total Assets
19 18 37 23 62 129 79 73 72 67
Total Current Assets
7.72 7.36 28 18 62 45 29 24 23 17
Cash & Equivalents
7.34 6.37 17 14 51 30 28 23 22 17
Note & Lease Receivable
- - - - - - - 0.72 0.13 0.02
Prepaid Expenses
0.23 0.31 0.84 0.98 0.34 0.72 0.60 0.28 0.45 0.38
Plant, Property, & Equipment, net
0.00 2.19 2.11 0.00 0.00 0.25 0.10 0.02 0.02 0.01
Plant, Property & Equipment, gross
- - - - - 0.25 0.10 0.02 0.02 0.01
Total Noncurrent Assets
11 8.25 6.82 4.39 0.09 83 50 49 49 49
Goodwill
- - - - - 13 8.14 8.14 8.14 8.14
Intangible Assets
9.30 7.80 6.39 4.24 0.00 70 41 41 41 41
Total Liabilities & Shareholders' Equity
19 18 37 23 62 129 79 73 72 67
Total Liabilities
2.82 11 26 9.86 6.80 20 11 12 5.38 2.76
Total Current Liabilities
1.60 5.19 14 7.40 1.58 3.26 3.41 1.68 1.93 2.15
Accounts Payable
1.60 5.19 12 7.32 1.49 3.16 3.34 1.68 1.93 2.15
Total Noncurrent Liabilities
1.21 1.25 12 2.46 5.22 17 7.76 9.87 3.45 0.61
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - 17 7.35 5.51 2.31 0.61
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
16 6.38 11 13 56 108 68 62 67 64
Total Preferred & Common Equity
16 6.38 11 13 56 108 68 62 67 64
Preferred Stock
- - - - - - - 0.00 0.00 0.00
Total Common Equity
16 6.38 11 13 56 108 68 62 67 64
Common Stock
54 62 119 147 208 270 272 279 293 298
Retained Earnings
-38 -56 -101 -126 -146 -156 -198 -211 -221 -228
Accumulated Other Comprehensive Income / (Loss)
- - -7.14 -7.89 -6.33 -6.04 -6.04 -6.04 -6.04 -6.04

Quarterly Balance Sheets for Grace Therapeutics

This table presents Grace Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q1 2027 Q2 2027
Period end date 6/30/2024 9/30/2023 12/31/2023 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025 6/30/2026 9/30/2026
Total Assets
70 78 76 65 61 70 67 68 50 58
Total Current Assets
20 29 27 16 12 21 17 19 14 22
Cash & Equivalents
19 27 19 15 11 20 17 19 14 21
Note & Lease Receivable
- - - 0.42 0.30 0.02 0.02 0.02 0.02 0.02
Prepaid Expenses
0.62 1.04 0.81 0.48 0.58 0.50 0.42 0.52 0.56 0.63
Plant, Property, & Equipment, net
0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01
Plant, Property & Equipment, gross
0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01
Total Noncurrent Assets
49 49 49 49 49 49 49 49 36 36
Goodwill
8.14 8.14 8.14 8.14 8.14 8.14 8.14 8.14 8.14 8.14
Intangible Assets
41 41 41 41 41 41 41 41 28 28
Total Liabilities & Shareholders' Equity
70 78 76 65 61 70 67 68 50 58
Total Liabilities
10 11 12 9.22 9.09 6.26 3.76 3.60 1.86 2.22
Total Current Liabilities
2.60 1.40 1.77 2.67 1.97 2.32 1.25 1.28 1.25 1.61
Accounts Payable
2.60 1.35 1.75 2.67 1.97 2.32 1.25 1.28 1.25 1.61
Total Noncurrent Liabilities
7.75 10 9.74 6.54 7.11 3.94 2.51 2.31 0.61 0.60
Noncurrent Deferred & Payable Income Tax Liabilities
4.79 6.61 6.40 3.94 3.33 2.31 2.31 2.31 0.61 0.60
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
59 67 65 56 52 64 63 65 48 55
Total Preferred & Common Equity
59 67 65 56 52 64 63 65 48 55
Preferred Stock
- - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
59 67 65 56 52 64 63 65 48 55
Common Stock
279 278 279 279 280 294 294 298 299 308
Retained Earnings
-214 -206 -208 -217 -221 -224 -225 -227 -244 -246
Accumulated Other Comprehensive Income / (Loss)
-6.04 -6.04 -6.04 -6.04 -6.04 -6.04 -6.04 -6.04 -6.04 -6.04

Annual Metrics And Ratios for Grace Therapeutics

This table displays calculated financial ratios and metrics derived from Grace Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 2/29/2016 2/28/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025 3/31/2026
DEI Shares Outstanding
0.00 0.00 25,638,215.00 78,132,734.00 78,132,734.00 179,495,705.00 44,288,183.00 44,612,831.00 9,399,404.00 10,139,861.00 10,139,861.00
DEI Adjusted Shares Outstanding
0.00 0.00 534,129.00 1,627,765.00 1,627,765.00 3,739,494.00 7,381,364.00 7,435,472.00 9,399,404.00 10,139,861.00 10,139,861.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -31.21 -24.18 -15.67 -5.26 -1.33 -5.71 -1.37 -0.94 -0.77
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -107.65% -140.39% -155.09% 25.26% 32.62% 44.19% -397.69% 70.08% 13.56% 24.50%
EBIT Growth
0.00% -68.93% -109.49% -136.14% 35.19% 22.87% 46.81% -398.87% 70.13% 13.58% 24.48%
NOPAT Growth
0.00% -9.82% -93.98% -125.33% 28.97% 32.81% 5.06% -234.56% 75.36% -29.78% 33.59%
Net Income Growth
0.00% -66.88% -112.07% -136.14% 35.19% 22.87% 50.10% -332.11% 69.71% 25.56% 18.55%
EPS Growth
0.00% -64.41% -26.80% 40.65% 58.90% -343.33% 79.70% -332.11% 76.36% 41.48% 40.51%
Operating Cash Flow Growth
0.00% 4.93% -108.24% -151.45% 194.05% -162.39% -20.36% 7.67% 22.50% -20.85% 40.49%
Free Cash Flow Firm Growth
0.00% 0.00% 79.52% -220.01% -181.15% 64.44% -754.67% 84.80% 37.73% -127.06% 41.45%
Invested Capital Growth
0.00% 0.00% -86.26% -1,186.96% 71.41% -52.69% 1,200.48% -37.65% -3.31% 14.81% 5.49%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -393.95% 61.96% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -401.86% 62.32% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 39.83% 19.29% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -401.86% 64.18% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -1,230.00% 80.58% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -28.00% -34.46% 0.00% 0.00% -6.17% 12.43%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -460.56% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% -109.10% -1.31% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 61.22% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% -9,568.37% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% -8,377.04% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -10,039.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% -10,039.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 98.78% 100.00% 100.00% 100.00% 100.00% 93.81% 81.64% 87.52% 74.94% 82.09%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.53% 94.16% 94.72% 93.27%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% -48.25% -147.09% -451.95% -212.26% -57.33% -11.98% -48.15% -19.82% -14.91% -11.94%
Cash Return on Invested Capital (CROIC)
0.00% -323.05% -58.17% 0.00% 0.00% 0.00% -126.07% -23.61% -19.46% -41.85% -22.31%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% -46.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% -46.13% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% -48.25% -147.09% -451.95% -212.26% -57.33% -11.98% -48.15% -19.82% -14.91% -11.94%
Return on Equity Simple (ROE_SIMPLE)
0.00% -48.25% -261.48% -356.41% -196.34% -35.35% -9.07% -62.44% -20.82% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-5.02 -5.51 -11 -24 -17 -11 -11 -37 -9.00 -12 -7.75
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -5,863.93% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
0.00% -64.10% -95.87% -103.38% -40.77% -20.90% 2.07% -16.47% -15.16% 9.34% -0.20%
Return On Investment Capital (ROIC_SIMPLE)
- - - -194.13% - - - - -14.57% -17.53% -12.14%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 38.78% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 2,816.84% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 2,129.08% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 8,438.27% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-4.71 -7.96 -17 -39 -26 -20 -10 -52 -16 -13 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-2.92 -6.07 -15 -37 -28 -19 -10 -52 -16 -13 -10
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 2.37 0.00 0.00 0.00 0.30 0.52 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 5.61 0.00 0.00 0.00 1.10 2.58 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.20 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -0.45 -0.55 -1.70 -1.72 -1.14 -0.64 -0.41 -0.39 -0.35 -0.30
Leverage Ratio
0.00 1.17 1.63 3.14 2.49 1.24 1.17 1.18 1.18 1.13 1.06
Compound Leverage Factor
0.00 1.17 1.63 3.14 2.49 1.24 1.17 1.17 1.11 1.07 0.99
Debt to Total Capital
0.00% 0.00% 16.39% 10.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 10.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 16.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 100.00% 83.61% 89.03% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 -0.09 -0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.35 0.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 -0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 -0.12 -0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.48 1.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 -0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 -6.27 0.00 0.00 0.00 -4.19 -2.70 0.00 0.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.00 4.81 1.42 2.05 2.50 39.50 13.89 8.59 14.26 11.77 8.10
Quick Ratio
0.00 4.67 1.34 1.97 2.00 38.80 13.56 8.41 14.09 11.53 7.92
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -14 -2.96 -9.48 -27 -9.48 -81 -12 -7.67 -17 -10
Operating Cash Flow to CapEx
-2,381.88% -248.18% -2,751.43% -4,639.43% 7,194.67% -20,752.17% 0.00% -93,605.88% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 1,001.89 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 21,160.39 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 -20,158.51 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.00 8.96 1.23 -13 -3.82 -5.84 64 40 39 44 47
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 -0.04 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 8.96 -7.73 -15 9.55 -2.02 70 -24 -1.33 5.74 2.44
Enterprise Value (EV)
0.00 0.00 0.00 1.73 0.00 0.00 0.00 -7.37 9.19 0.00 0.00
Market Capitalization
0.00 0.00 0.00 26 0.00 0.00 0.00 21 32 0.00 0.00
Book Value per Share
$0.00 $1.51 $0.36 $0.43 $0.17 $0.31 $2.44 $1.52 $6.57 $5.51 $3.87
Tangible Book Value per Share
$0.00 $0.65 ($0.08) $0.18 $0.11 $0.31 $0.58 $0.42 $1.33 $1.43 $0.89
Total Capital
0.00 16 7.63 12 13 56 108 68 62 67 64
Total Debt
0.00 0.00 1.25 1.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 1.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -7.34 -5.15 -24 -14 -61 -44 -28 -23 -22 -17
Capital Expenditures (CapEx)
0.21 1.88 0.35 0.53 0.32 0.07 0.00 0.02 -0.09 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -1.22 -4.21 -10 -3.17 0.06 -1.64 -2.01 -0.68 -1.35 -1.74
Debt-free Net Working Capital (DFNWC)
0.00 6.11 2.17 16 11 61 42 26 22 21 15
Net Working Capital (NWC)
0.00 6.11 2.17 14 11 61 42 26 22 21 15
Net Nonoperating Expense (NNE)
-0.31 2.35 5.98 15 8.41 8.18 -1.09 5.92 3.86 -2.11 0.04
Net Nonoperating Obligations (NNO)
0.00 -7.34 -5.15 -24 -17 -61 -44 -28 -23 -22 -17
Total Depreciation and Amortization (D&A)
1.79 1.88 2.07 2.12 -2.32 0.92 0.00 0.12 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 31.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 31,016.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 31,016.84% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 ($45.60) $0.00 ($0.17) ($0.27) ($5.70) ($1.35) ($0.79) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 25.64M 1.63M 92.49M 208.38M 44.44M 7.44M 9.53M 12.09M 16.51M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 ($45.60) $0.00 ($0.17) ($0.27) ($5.70) ($1.35) ($0.79) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 25.64M 1.63M 92.49M 208.38M 44.44M 7.44M 9.53M 12.09M 16.51M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($45.60) $0.00 ($0.17) ($0.27) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 17.49M 1.13M 92.49M 118.63M 36.84M 7.44M 9.40M 0.00 16.27M
Normalized Net Operating Profit after Tax (NOPAT)
-5.02 -5.51 -11 -24 -17 -7.50 -11 -13 -7.96 -12 -7.75
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -3,827.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% -10,039.80% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.02% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% -1.26% -10.11% -4.20%

Quarterly Metrics And Ratios for Grace Therapeutics

This table displays calculated financial ratios and metrics derived from Grace Therapeutics' official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 Q1 2027 Q2 2027
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
7,448,033.00 9,399,404.00 9,399,404.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 16,274,026.00 21,035,930.00
DEI Adjusted Shares Outstanding
7,448,033.00 9,399,404.00 9,399,404.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 10,139,861.00 16,274,026.00 21,035,930.00
DEI Earnings Per Adjusted Shares Outstanding
-0.44 -0.25 -0.49 -0.34 -0.41 -0.33 -0.09 -0.23 -0.12 -0.97 -0.10
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% 0.00% 0.00% -13.59% -68.02% 0.00% 75.09% 49.31% 0.00% -343.25% -106.49%
EBIT Growth
0.00% 0.00% 0.00% -13.36% -68.03% 0.00% 75.09% 49.27% 0.00% -343.06% -106.58%
NOPAT Growth
0.00% 0.00% 0.00% -130.93% -21.72% 0.00% 47.65% 33.88% 0.00% -415.11% 9.37%
Net Income Growth
0.00% 0.00% 0.00% -4.86% -73.78% 0.00% 72.67% 44.28% 0.00% -369.66% -127.19%
EPS Growth
0.00% 0.00% 0.00% 30.23% -71.43% 0.00% 80.00% 61.11% 0.00% -333.33% -83.33%
Operating Cash Flow Growth
0.00% 0.00% 0.00% 0.00% -117.49% 0.00% 0.00% 45.81% 42.62% -78.85% 43.24%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -46.79% -66.64% 0.00% 0.00% 250.58%
Invested Capital Growth
0.00% 0.00% 0.00% 3.08% 3.84% 0.00% 12.19% 12.50% 0.00% -20.88% -25.65%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-9.73% 25.72% -77.52% 0.00% -9.87% 0.00% 68.86% -123.60% -21.43% -424.29% 85.50%
EBIT Q/Q Growth
-9.93% 25.85% -77.50% 0.00% -9.92% 0.00% 68.88% -123.87% -21.37% -424.01% 85.49%
NOPAT Q/Q Growth
57.85% -45.46% 9.50% 0.00% 23.33% 0.00% 18.16% 3.16% -22.87% -428.98% 85.60%
Net Income Q/Q Growth
-25.07% 26.95% -91.22% 0.00% -21.07% 0.00% 72.10% -146.80% 49.11% -1,240.41% 86.50%
EPS Q/Q Growth
-79.17% 51.16% -128.57% 0.00% -20.00% 0.00% 71.43% -133.33% 57.14% -1,416.67% 87.91%
Operating Cash Flow Q/Q Growth
-32.29% 60.23% -10.36% 0.00% 0.00% 39.03% -74.51% 29.05% 23.99% -90.03% 44.61%
Free Cash Flow Firm Q/Q Growth
100.00% 0.00% 0.00% 0.00% 10.76% 0.00% 0.00% -1.30% 100.00% 0.00% 596.25%
Invested Capital Q/Q Growth
-0.54% -0.44% -2.09% 0.00% 0.29% 0.00% 5.54% 0.57% 1.51% -26.56% -0.83%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
88.01% 92.00% 90.97% 80.11% 87.29% 100.00% 100.00% 100.00% 40.93% 100.00% 99.63%
Interest Burden Percent
94.61% 89.16% 97.14% 96.14% 97.18% 94.25% 84.50% 93.16% 95.42% 99.91% 93.28%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% 0.00% -19.82% 0.00% 0.00% 0.00% 0.00% 0.00% -11.94% -36.19% -36.20%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -19.80% 0.00% 0.00% 0.00% 0.00% 0.00% -21.73% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% 0.00% -19.82% 0.00% 0.00% 0.00% 0.00% 0.00% -11.94% -36.19% -36.20%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-1.46 -2.13 -1.93 -3.38 -2.59 -2.16 -1.77 -1.71 -2.11 -11 -1.60
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-6.70% -1.04% -11.49% -0.24% -8.64% -5.99% 5.20% -4.04% 5.47% -27.54% -2.76%
Return On Investment Capital (ROIC_SIMPLE)
- -3.29% -3.12% -6.02% -4.97% -3.40% -2.82% -2.64% -3.30% -23.11% -2.89%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.93 -2.92 -5.17 -4.46 -4.90 -3.57 -1.11 -2.49 -3.02 -16 -2.29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.92 -2.91 -5.17 -4.46 -4.90 -3.57 -1.11 -2.48 -3.01 -16 -2.29
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.42 0.52 0.54 0.73 0.00 0.00 0.00 0.00 0.77 0.82
Price to Tangible Book Value (P/TBV)
0.00 1.76 2.58 4.43 13.20 0.00 0.00 0.00 0.00 2.96 2.29
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.05 0.24 0.37 0.65 0.00 0.00 0.00 0.00 0.67 0.70
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.40 -0.39 -0.37 -0.34 -0.31 -0.31 -0.27 -0.25 -0.27 -0.30 -0.32
Leverage Ratio
1.17 1.18 1.18 1.17 1.18 1.10 1.11 1.11 1.06 1.07 1.05
Compound Leverage Factor
1.11 1.05 1.14 1.12 1.14 1.04 0.94 1.03 1.01 1.07 0.98
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 -2.23 0.00 0.00 0.00 0.00 0.00 0.00 4.35 6.55
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
20.68 15.19 14.26 6.01 6.06 8.87 13.89 14.96 8.10 11.47 13.61
Quick Ratio
19.93 14.73 14.09 5.83 5.76 8.65 13.56 14.56 7.92 11.02 13.22
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 0.00 0.00 -4.61 -4.11 0.00 -6.76 -6.85 0.00 -2.05 10
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
40 40 39 41 41 44 46 46 47 34 34
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 0.00 0.00 1.23 1.52 0.00 4.99 5.14 0.00 -9.09 -12
Enterprise Value (EV)
0.00 2.05 9.19 15 27 0.00 0.00 0.00 0.00 23 24
Market Capitalization
0.00 27 32 30 38 0.00 0.00 0.00 0.00 37 45
Book Value per Share
$8.96 $6.88 $6.57 $5.54 $5.14 $3.99 $3.94 $3.83 $3.87 $2.96 $2.64
Tangible Book Value per Share
$2.35 $1.64 $1.33 $0.68 $0.28 $0.90 $0.85 $0.92 $0.89 $0.77 $0.94
Total Capital
67 65 62 56 52 64 63 65 64 48 55
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-27 -25 -23 -15 -11 -20 -17 -19 -17 -14 -21
Capital Expenditures (CapEx)
0.00 0.00 -0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.48 0.00 -0.68 -1.78 -1.09 -1.80 -0.81 -0.75 -1.74 -0.67 -0.97
Debt-free Net Working Capital (DFNWC)
27 25 22 13 9.97 18 16 18 15 13 20
Net Working Capital (NWC)
27 25 22 13 9.97 18 16 18 15 13 20
Net Nonoperating Expense (NNE)
1.81 0.26 2.64 0.05 1.56 1.20 -0.83 0.60 -0.93 4.65 0.53
Net Nonoperating Obligations (NNO)
-27 -25 -23 -15 -11 -20 -17 -19 -17 -14 -21
Total Depreciation and Amortization (D&A)
0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06) ($0.91) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding
7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M 17.27M 20.12M
Adjusted Diluted Earnings per Share
($0.43) ($0.21) ($0.48) ($0.30) ($0.36) ($0.21) ($0.06) ($0.14) ($0.06) ($0.91) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding
7.55M 11.51M 9.53M 11.51M 11.51M 15.92M 15.92M 16.93M 16.51M 17.27M 20.12M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 ($0.48) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
9.40M 9.40M 9.40M 10.14M 0.00 0.00 0.00 0.00 16.27M 21.04M 21.04M
Normalized Net Operating Profit after Tax (NOPAT)
-1.46 -2.13 -0.89 -3.38 -2.59 -2.16 -1.77 -1.71 -2.11 -1.67 -1.60
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -1.26% 0.00% 0.00% 0.00% 0.00% 0.00% -4.20% 0.00% -3.09%

Financials Breakdown Chart

Key Financial Trends

Grace Therapeutics (NASDAQ: GRCE) remains a development-stage company with no reported revenue across the periods provided. The latest quarter, Q1 fiscal 2027 ended June 30, 2026, again reported zero revenue and zero gross profit, leaving the company dependent on cash reserves and potential future financing or product commercialization.

The most recent results show some improvement in operating cost control, but this was overwhelmed by a large impairment charge. Grace reported a net loss of $15.8 million, including a $13.5 million impairment charge, compared with losses of $1.2 million in Q4 fiscal 2026 and $2.3 million in Q3 fiscal 2026.

  • Liquidity remains substantial relative to near-term obligations. Grace held $13.8 million in cash and equivalents at June 30, 2026, compared with $1.9 million in total liabilities and $1.25 million in current liabilities. This represents a current ratio of approximately 11.5 times.
  • Total liabilities have declined materially. Liabilities fell from $11.5 million in Q3 fiscal 2024 to $1.9 million in the latest quarter, reducing balance-sheet leverage and near-term creditor pressure.
  • Operating expenses excluding the impairment charge have moderated. SG&A declined to $1.7 million in Q1 fiscal 2027 from $2.6 million in Q4 fiscal 2026, while research and development expense increased to $697,000 from $420,000.
  • Interest and investment income provides a modest offset to operating losses. The company generated $141,000 of interest and investment income in the latest quarter, supported by its cash balance.
  • Financing has historically provided access to capital. Grace reported $14.0 million of financing cash flow in Q4 fiscal 2025 and $4.0 million in Q3 fiscal 2026, although this source of funding has not been consistent.
  • The balance sheet is heavily weighted toward intangible assets. Intangible assets totaled $27.6 million and goodwill totaled $8.1 million at June 30, 2026, together representing roughly 71% of total assets. The value of these assets depends on the successful development and commercialization of the company’s products.
  • Recent balance-sheet changes partly reflect impairment accounting rather than cash generation. Intangible assets declined from $41.1 million to $27.6 million, while the company recorded a $13.5 million impairment charge. This reduced reported assets but did not represent a comparable cash outflow in the quarter.
  • Grace has not generated revenue in the reported periods. Each provided income statement shows zero revenue, meaning the company has no demonstrated operating sales to fund research, administration or other corporate expenses.
  • Cash burn remains persistent. Net cash used in operating activities was $3.2 million in Q1 fiscal 2027, following outflows of $1.7 million in Q4 fiscal 2026, $2.2 million in Q3 fiscal 2026 and $3.1 million in Q2 fiscal 2026. Cash declined from $20.0 million at June 30, 2025, to $13.8 million one year later.
  • Accumulated losses and dilution risk remain significant. Retained earnings were negative $244.3 million at June 30, 2026, while the weighted-average basic share count increased to 17.3 million in Q1 fiscal 2027 from 11.5 million in the comparable fiscal 2024 quarter. Additional capital raises could further dilute existing shareholders.

Overall, Grace Therapeutics has a relatively strong near-term liquidity position and limited liabilities, but its financial profile remains highly speculative. The company continues to consume cash without revenue, has accumulated substantial losses, and recently recognized a major impairment of intangible assets. Investors should focus on cash runway, future financing activity, clinical or regulatory progress, and evidence that the company can eventually convert its development pipeline into commercial revenue.

11/20/26 04:08 PM ETAI Generated. May Contain Errors.

Grace Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Grace Therapeutics' fiscal year ends in March. Their fiscal year 2026 ended on March 31, 2026.

In the past 10 years, Grace Therapeutics' net income has ranged from -$42.43 million in 2023 to -$4.71 million in 2016, and is currently -$7.79 million as of their latest financial filing in 2026. See where experts think Grace Therapeutics is headed by visiting Grace Therapeutics' forecast page.

Grace Therapeutics' total operating income in 2026 was -$11.08 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.08 million

Over the last 10 years, Grace Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2026, a change of 0.0%.

In the past 13 quarters, Grace Therapeutics' cash and equivalents has ranged from $11.06 million in Q3 2025 to $26.99 million in Q2 2024, and is currently $21.31 million as of their latest financial filing in Q2 2027.

Grace Therapeutics had total debt of $0.00 at the end of 2026, compared with none in 2025, and none in 2016.

Over the last 10 years, Grace Therapeutics' book value per share changed from 0.00 in 2016 to 3.87 in 2026, a change of 387.0%.



Financial statements for NASDAQ:GRCE last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners